ACT-462206: Clinical Trials

1 trial of ACT-462206, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 11Completed 1

Follow ACT-462206: new trials by email Literature Review of ACT-462206 trials Research Report on ACT-462206

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206
ACT-462206 5 mg, ACT-462206 25 mg, ACT-462206 100mg - Safety, Tolerability
Phase 1CompletedIdorsia Pharmaceuticals Ltd.562011-11-012018-07-10

Sponsors

Idorsia Pharmaceuticals Ltd. (1)

Countries

Netherlands (1)

Top investigators

Petra Baecker, MD (1)